"An experimental non-surgical treatment method has demonstrated strong results in fighting a form of bladder cancer, according to new research. The type of cancer, known as BCG-unresponsive high-risk non-muscle-invasive bladder cancer, is difficult to treat and has previously relied on bladder removal surgery. However, a new breakthrough treatment known as Inlexzo, tested by Janssen Research & Development, a subsidiary of Johnson & Johnson, may offer a more preferable alternative to surgery."
"Study lead Sia Daneshmand said: Traditionally, these patients have had very limited treatment options. This new therapy is the most effective one reported to date for the most common form of bladder cancer. A new breakthrough' treatment may offer a more preferable alternative to surgery (Johnson & Johnson) He continued: "The findings of the clinical trial are a breakthrough in how certain types of bladder cancer might be treated, leading to improved outcomes and saved lives.""
The Independent emphasizes on-the-ground reporting across reproductive rights, climate change, and technology while avoiding paywalls and seeking donations to fund journalism. An experimental non-surgical treatment called Inlexzo, tested by Janssen Research & Development (a Johnson & Johnson subsidiary), has shown strong results against BCG-unresponsive high-risk non-muscle-invasive bladder cancer. The therapy eliminated tumours that had resisted prior treatment in 82 per cent of patients. Study lead Sia Daneshmand described the clinical trial's findings as a breakthrough that could improve outcomes and save lives.
Read at www.independent.co.uk
Unable to calculate read time
Collection
[
|
...
]